HC Wainwright Has Negative Outlook of JANX FY2030 Earnings

Janux Therapeutics, Inc. (NASDAQ:JANX) – Analysts at HC Wainwright lowered their FY2030 earnings per share (EPS) estimates for shares of Janux Therapeutics in a research report issued to clients and investors on Monday, August 10th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings of $0.97 per share for the year, down from their prior forecast of $1.06. The consensus estimate for Janux Therapeutics’ current full-year earnings is ($1.70) per share.

Janux Therapeutics (NASDAQ:JANX) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.10). The business had revenue of $10.27 million during the quarter, compared to analyst estimates of $19.07 million.

Several other brokerages also recently issued reports on JANX. Truist Financial reiterated a “buy” rating and issued a $26.00 target price (down from $80.00) on shares of Janux Therapeutics in a research note on Thursday, June 25th. Guggenheim cut their target price on Janux Therapeutics from $58.00 to $55.00 and set a “buy” rating on the stock in a research note on Friday. Wedbush decreased their price target on Janux Therapeutics from $45.00 to $36.00 and set an “outperform” rating for the company in a research note on Friday, May 8th. Stifel Nicolaus set a $35.00 price objective on Janux Therapeutics in a report on Friday. Finally, Piper Sandler lowered their target price on shares of Janux Therapeutics from $30.00 to $26.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. Nine research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, Janux Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $37.58.

Janux Therapeutics Price Performance

Shares of Janux Therapeutics stock opened at $16.41 on Tuesday. Janux Therapeutics has a 1 year low of $12.12 and a 1 year high of $35.34. The firm’s 50-day moving average is $15.08 and its 200 day moving average is $14.47. The stock has a market cap of $1.00 billion, a price-to-earnings ratio of -10.01 and a beta of 2.50.

Institutional Investors Weigh In On Janux Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. bought a new stake in Janux Therapeutics during the 2nd quarter valued at approximately $94,228,000. State Street Corp lifted its holdings in shares of Janux Therapeutics by 103.8% in the 4th quarter. State Street Corp now owns 3,853,951 shares of the company’s stock worth $53,185,000 after acquiring an additional 1,962,486 shares during the last quarter. Prosight Management LP boosted its position in shares of Janux Therapeutics by 176.5% during the fourth quarter. Prosight Management LP now owns 2,392,523 shares of the company’s stock valued at $33,017,000 after buying an additional 1,527,173 shares during the period. Wellington Management Group LLP raised its stake in shares of Janux Therapeutics by 129.5% during the fourth quarter. Wellington Management Group LLP now owns 1,610,186 shares of the company’s stock valued at $22,221,000 after acquiring an additional 908,582 shares in the last quarter. Finally, Balyasny Asset Management L.P. bought a new stake in Janux Therapeutics during the 4th quarter valued at $12,221,000. 75.39% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Janux Therapeutics news, insider Janeen Noel Doyle sold 4,059 shares of the company’s stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $14.03, for a total value of $56,947.77. Following the completion of the transaction, the insider directly owned 75,941 shares in the company, valued at $1,065,452.23. This represents a 5.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 7.90% of the stock is owned by corporate insiders.

Janux Therapeutics Company Profile

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.